Clinical Trial Results Indicate Acthar May Significantly Reduce Disease Activity in Patients with Systemic Lupus Erythematosus

[PR Newswire] – ANAHEIM, Calif., May 5, 2014 /PRNewswire/ — Questcor Pharmaceuticals, Inc. (QCOR) today announced that results from the first modern clinical study examining the use of H.P. Acthar® Gel (repository corticotropin injection) in systemic l more

View todays social media effects on QCOR

View the latest stocks trending across Twitter. Click to view dashboard

See who Questcor is hiring next, click here to view